Search results
Massive study identifies new biomarkers for renal cancer subtypes, improving diagnosis...
Medical Xpress· 4 days agoThe findings lay the groundwork to identify therapeutic targets in non-clear-cell renal cell carcinomas. ...
New PET agent provides same-day imaging for clear cell renal cell carcinoma patients
Medical Xpress· 3 days agoA novel investigational PET imaging agent can rapidly and accurately visualize lesions in clear cell renal cell cancer (ccRCC) patients ...
Targeting CXCR4 impaired T regulatory function through PTEN in renal cancer patients - British...
Nature· 7 days agoTregs trafficking is controlled by CXCR4. In Renal Cell Carcinoma (RCC), the effect of the new CXCR4 antagonist, R54, was explored in ...
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Zacks via Yahoo Finance· 5 hours agoIovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for...
YOUR HEALTH: Why some kidney cancer patients are living longer
WAFB Baton Rouge· 2 days agoKidney cancer is among the 10 most common cancers in both men and women. A decade ago, advanced...
Fighting Cancer: A Basic Guide To Checkpoint Inhibitors
Forbes· 5 days agoThis article is part of an ongoing series on novel cancer advances, including immunotherapies such...
Bavencio Side Effects: What They Are and How to Manage Them
Healthline· 3 days agoBavencio (avelumab) is a prescription drug used to treat certain types of kidney, bladder, and skin cancer. Bavencio can cause side effects that range from mild to serious. Examples include ...
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 4 days agoInvestors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for...
Plasma proteome profiling reveals dynamic of cholesterol marker after dual blocker therapy - Nature...
Nature· 3 days agoDual blockade therapy is currently being trialled for multiple tumour types, but efficacy is variable. Here, the authors use longitudinal proteomics profiling of 22 patients to develop a predictive model of therapy response.
Exelixis (NASDAQ:EXEL) Earns “Outperform” Rating from William Blair
ETF DAILY NEWS· 7 days agoWilliam Blair reaffirmed their outperform rating on shares of Exelixis (NASDAQ:EXEL – Free Report) in a report published on Wednesday, RTT News reports. Barclays lowered Exelixis from an overweight ...